Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
Acadia Pharmaceuticals (Nasdaq: ACAD) announced it will report its second quarter financial results on August 6, 2024, post market close. The management team will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results and operations. The call will be accessible via Acadia's website under the investors section and archived until September 6, 2024. Participants can register online to receive a dial-in number and unique PIN for the call. Acadia Pharmaceuticals specializes in developing treatments for neuropsychiatric conditions and has FDA-approved drugs for Parkinson’s disease psychosis and Rett syndrome. The company is also conducting clinical-stage research on Prader-Willi syndrome and Alzheimer’s disease psychosis.
Acadia Pharmaceuticals (Nasdaq: ACAD) ha annunciato che rilascerà i propri risultati finanziari del secondo trimestre il 6 agosto 2024, dopo la chiusura del mercato. Il team di gestione terrà una call e webcast di conferenza alle 16:30 ora dell'Est dello stesso giorno per discutere i risultati finanziari e le operazioni. La chiamata sarà accessibile tramite il sito web di Acadia nella sezione investitori e sarà archiviata fino al 6 settembre 2024. I partecipanti possono registrarsi online per ricevere un numero di chiamata e un PIN unico per la conferenza. Acadia Pharmaceuticals si specializza nello sviluppo di trattamenti per condizioni neuropsichiatriche e dispone di farmaci approvati dalla FDA per la psicosi del morbo di Parkinson e la sindrome di Rett. L'azienda sta inoltre conducendo ricerche cliniche sullo sdoppiamento nello spettro di Prader-Willi e sulla psicosi della malattia di Alzheimer.
Acadia Pharmaceuticals (Nasdaq: ACAD) anunció que reportará sus resultados financieros del segundo trimestre el 6 de agosto de 2024, después del cierre del mercado. El equipo directivo llevará a cabo una conferencia telefónica y webcast a las 4:30 p.m. Hora del Este del mismo día para discutir los resultados financieros y las operaciones. La llamada será accesible a través del sitio web de Acadia en la sección de inversionistas y se archivará hasta el 6 de septiembre de 2024. Los participantes pueden registrarse en línea para recibir un número de acceso y un PIN único para la llamada. Acadia Pharmaceuticals se especializa en el desarrollo de tratamientos para condiciones neuropsiquiátricas y cuenta con medicamentos aprobados por la FDA para la psicosis del enfermedad de Parkinson y la síndrome de Rett. La compañía también está llevando a cabo investigaciones en fase clínica sobre el síndrome de Prader-Willi y la psicosis de la enfermedad de Alzheimer.
아카디아 제약 (Nasdaq: ACAD)는 2024년 8월 6일에 2분기 재무 결과를 시장 마감 후 발표할 것이라고 발표했습니다. 경영진은 같은 날 미국 동부 시간으로 오후 4시 30분에 재무 결과와 운영에 대해 논의하기 위해 컨퍼런스 콜 및 웹캐스트를 주최합니다. 이 통화는 아카디아의 웹사이트 투자자 섹션에서 접근할 수 있으며 2024년 9월 6일까지 아카이브됩니다. 참여자는 온라인으로 등록하여 통화에 대한 전화 번호와 고유 PIN을 받을 수 있습니다. 아카디아 제약은 신경정신적 상태 치료제를 개발하는 데 전문화되어 있으며 파킨슨병 정신증과 레트 증후군에 대한 FDA 승인을 받은 약물이 있습니다. 이 회사는 또한 프라더-윌리 증후군과 알츠하이머병 정신증에 대한 임상 연구를 진행하고 있습니다.
Acadia Pharmaceuticals (Nasdaq: ACAD) a annoncé qu'il publiera ses résultats financiers du deuxième trimestre le 6 août 2024, après la clôture du marché. L'équipe de direction organisera une conférence téléphonique et un webinaire le même jour à 16h30, heure de l'Est, pour discuter des résultats financiers et des opérations. L'appel sera accessible via le site web d'Acadia dans la section investisseurs et sera archivé jusqu'au 6 septembre 2024. Les participants peuvent s'inscrire en ligne pour recevoir un numéro d'appel et un code PIN unique pour la conférence. Acadia Pharmaceuticals se spécialise dans le développement de traitements pour les troubles neuropsychiatriques et possède des médicaments approuvés par la FDA pour la psychose de la maladie de Parkinson et le syndrome de Rett. L'entreprise mène également des recherches cliniques sur le syndrome de Prader-Willi et la psychose de la maladie d'Alzheimer.
Acadia Pharmaceuticals (Nasdaq: ACAD) gab bekannt, dass es seine Finanzergebnisse für das zweite Quartal am 6. August 2024 nach Börsenschluss veröffentlichen wird. Das Management-Team wird am selben Tag um 16:30 Uhr Eastern Time eine Konferenzschaltung und Webcast veranstalten, um die Finanzergebnisse und betrieblichen Abläufe zu besprechen. Der Anruf wird über die Website von Acadia im Investorenbereich zugänglich sein und bis zum 6. September 2024 archiviert werden. Teilnehmer können sich online registrieren, um eine Einwahlnummer und einen einzigartigen PIN für den Anruf zu erhalten. Acadia Pharmaceuticals ist auf die Entwicklung von Behandlungen für neuropsychiatrische Erkrankungen spezialisiert und hat von der FDA genehmigte Medikamente gegen die Psychose der Parkinson-Krankheit und das Rett-Syndrom. Das Unternehmen führt außerdem klinische Forschungsarbeiten zu Prader-Willi-Syndrom und Alzheimer-Psychose durch.
- Acadia Pharmaceuticals to announce second quarter financial results, which may provide insights into company's performance.
- Upcoming conference call and webcast offers transparency on financial results and operations.
- None.
Company to host conference call and webcast on Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time
The conference call will be available on Acadia’s website, Acadia.com under the investors section and will be archived there until September 6, 2024. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724261503/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
When will Acadia Pharmaceuticals announce their second quarter financial results?
What time is Acadia Pharmaceuticals' Q2 2024 conference call?
Where can I access Acadia Pharmaceuticals' Q2 2024 conference call?
What is the stock symbol for Acadia Pharmaceuticals?
What clinical-stage developments is Acadia Pharmaceuticals involved in?
